For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
42
views
158
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      87
      similar
       All similar

      Neuropsychiatric Disease and Treatment (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on all aspects of neuropsychiatric and neurological disorders. Sign up for email alerts here.

      63,741 Monthly downloads/views I 2.989 Impact Factor I 4.5 CiteScore I 1.09 Source Normalized Impact per Paper (SNIP) I 0.744 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Traditional Chinese Medicine Jiuwei Zhenxin Granules in Treating Depression: An Overview

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Depression is known as “Yu Zheng” in traditional Chinese medicine (TCM). Jiuwei Zhenxin granules (JZG) is a type of TCM. According to TCM theory, it nourishes the heart and spleen, tonifies Qi, and tranquilizes the spirit, and may also has effects in the treatment of depression. Here, we systematically reviewed recent basic and clinical experimental studies of JZG and depression, including studies of the pharmacological mechanisms, active ingredients, and clinical applications of JZG in depression treatment. This review will deepen our understanding of the pharmacological mechanisms, drug interactions, and clinical applications of TCM prescriptions and provide a basis for the development of new drugs in the treatment of depression.

          Most cited references158

          • Record: found
          • Abstract: not found
          • Article: not found

          Mental health: a world of depression.

          Kerri Smith (2014)
          Article 0 comments Cited 347 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.

            Anthony Grace (2016)
            The dopamine system is unique among the brain's modulatory systems in that it has discrete projections to specific brain regions involved in motor behaviour, cognition and emotion. Dopamine neurons exhibit several activity patterns - including tonic and phasic firing - that are determined by a combination of endogenous pacemaker conductances and regulation by multiple afferent systems. Emerging evidence suggests that disruptions in these regulatory systems may underlie the pathophysiology of several psychiatric disorders, including schizophrenia and depression.
            Article 0 comments Cited 338 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

              Rebecca B Price, Matthew Nock, Dennis Charney … (2009)
              Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment. Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period. Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42). These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
              Article 0 comments Cited 176 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Neuropsychiatr Dis Treat
                Journal ID (iso-abbrev): Neuropsychiatr Dis Treat
                Journal ID (publisher-id): ndt
                Journal ID (pmc): neurodist
                Title: Neuropsychiatric Disease and Treatment
                Publisher: Dove
                ISSN (Print): 1176-6328
                ISSN (Electronic): 1178-2021
                Publication date (Electronic): 02 October 2020
                Publication date Collection: 2020
                Volume: 16
                Pages: 2237-2255
                Affiliations
                [1 ]Department of Critical Care Medicine, Shengjing Hospital of China Medical University , Shenyang, Liaoning, People’s Republic of China
                Author notes
                Correspondence: Xingmao WuDepartment of Critical Care Medicine, Shengjing Hospital of China Medical University , Heping District, Shenyang, Liaoning110004, People’s Republic of China Tel/Fax +86 24 18940251899 Email cmu_xingmaowu@sina.com
                Article
                Publisher ID: 273324
                DOI: 10.2147/NDT.S273324
                PMC ID: 7541918
                SO-VID: fc9f63a7-e145-4b37-a346-3bce57383626
                Copyright © © 2020 Wang and Wu.
                License:

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                Date received : 22 July 2020
                Date accepted : 07 September 2020
                Page count
                Figures: 5, Tables: 6, References: 158, Pages: 19
                Funding
                There is no funding to report.
                Categories
                Subject: Review

                ScienceOpen disciplines: Neurology
                Keywords: jiuwei zhenxin granules,depression,yu zheng,pharmacological,effective substance
                Data availability:
                ScienceOpen disciplines: Neurology
                Keywords: jiuwei zhenxin granules, depression, yu zheng, pharmacological, effective substance

                Comments

                Comment on this article

                scite_

                Similar content87

                See all similar

                Cited by2

                See all cited by

                Most referenced authors1,612

                See all reference authors